eNOS-β-actin Peptide Inhibitors for Oxygen Toxicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for managing oxygen toxicity, particularly in the lungs, are inadequate as they fail to effectively inhibit or reduce the harmful effects of high oxygen concentrations, leading to conditions like pulmonary oxygen toxicity and retrolental fibroplasia in premature infants.
Innovation Solution
The development of compositions and methods that inhibit the intracellular interaction between endothelial nitric oxide synthase (eNOS) and β-actin, using specific polypeptides that mask binding sites or compete for binding, thereby reducing the production of reactive oxygen species such as nitric oxide and peroxynitrite, which cause lung damage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Temperature
If supplemental oxygen is administered to treat hypoxia, then oxygenation of blood is improved, but oxygen toxicity and oxidative stress increase
Solution Approach 1:
The patent uses a peptide inhibitor as an intermediary substance that specifically blocks the interaction between eNOS and β-actin. This mediator prevents the formation of reactive oxygen species without interfering with the beneficial oxygenation effects, thus resolving the contradiction between improving oxygenation and preventing oxygen toxicity
Solution Approach 2:
The invention extracts and isolates the specific pathological mechanism (eNOS-β-actin interaction) that leads to oxygen toxicity. By targeting and inhibiting this specific interaction, the patent removes the harmful effect while preserving the necessary oxygenation function
2Reliability
If high concentrations of oxygen are delivered to prevent hypoxia, then survival is improved, but lung injury and chronic lung disease develop
Solution Approach 1:
The patent applies preliminary anti-action by administering the peptide inhibitor before or during oxygen therapy to preemptively block the pathological eNOS-β-actin interaction. This prevents the development of lung injury and chronic lung disease while allowing the survival benefits of oxygen therapy to be realized
3Object-affected harmful factors
If antioxidants are administered to counteract oxidative stress, then cell damage is reduced, but treatment effectiveness is limited
Solution Approach 1:
Instead of using antioxidants to counteract oxidative stress after it occurs, the patent inverts the approach by preventing the formation of reactive oxygen species at their source through inhibition of the eNOS-β-actin interaction. This upstream prevention strategy is more effective than downstream antioxidant treatment
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compositions effectively reduce lung injury from hyperoxia by inhibiting the association between eNOS and β-actin, thereby decreasing the production of harmful reactive oxygen species, thereby mitigating oxygen toxicity and its associated damages.
Implementation Method 1
increased association of endothelial nitric oxide synthases (eNOS) with β-actin in pulmonary artery endothelial cells (PAEC) contributes to hyperoxia-induced increase in the production of nitric oxide and peroxynitrite
Implementation Method 2
hyperoxia-induced increase in the production of nitric oxide and peroxynitrite which can cause lung damage
Data Source
AI summary
Compositions and methods for inhibiting the interaction between eNOS and β-actin are provided for use in inhibiting or reducing lung injury from oxygen toxicity. One embodiment provides a synthetic or recombinant polypeptide having the β-actin binding domain of eNOS, wherein the polypeptide inhibits or reduces eNOS activity in lung endothelial cells.